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Introduction
Prostate cancer is the most common cancer in Sweden (8,870 new cases in 2007) accounting for approximately one third of all cancer diagnoses among men (Socialstyrelsens Cancerregistret 2009, http://www.roc.se/cancerreg.asp). The worldwide prevalence is increasing and approximately one out of six men will be diagnosed with prostate cancer. The clinical course of the disease varies and the majority of the patients will eventually die of other causes than prostate cancer.
Quantitative analysis of the prostate specific antigen (PSA) in plasma is a corner stone both for diagnosing and monitoring the disease [1; 2] . Approximately, 25 million PSA tests were performed worldwide in 2005 (Clinical Data, Inc., Newton, MA, http://www.clda.com).
Although, PSA is the clinically most valuable tumor marker used, it is associated with considerable specificity and sensitivity problems. Increased PSA values can result from malignant as well as benign prostate disease, e.g., hyperplasia or prostatitis. Consequently, 65-75% of men who undergo a prostate biopsy due to a moderate PSA elevation (≈3-10 ng/mL, ref. value <3 ng/mL) do not have evidence of cancer [3; 4] and 25% of men with PCa have normal PSA levels [5] .
To improve the specificity, two molecular forms of PSA are routinely analyzed: free PSA (fPSA) and total PSA (tPSA = the sum of fPSA and PSA in complex with 1 -antichymotrypsin, SERPINA3). The level of fPSA is lower in men with malignant disease than in men with benign hyperplasia. Yet, there is no clear-cut method to distinguish the various forms of prostate disease.
In order to improve its clinical value, new immunoassays for different molecular forms of PSA, e.g., pro-PSA, intact PSA and BPSA (a PSA variant internally cleaved at Lys182/Ser183 [6; 7] ) have been developed but so far no substantial increment in diagnostic accuracy compared to analysis of tPSA and fPSA [8] has been demonstrated.
PSA is a serine protease produced by the epithelial cells of the prostate and secreted as an inactive proenzyme (proPSA) into seminal fluid [4; 9] , where it can be activated by the kallikrein-related peptidase 2 (hK2) and other endopeptidases of the prostate [4; [10] [11] [12] . PSA has restricted chymotrypsin-like endoproteolytic activity, cleaving its biological substrates, semenogelin 1 and 2 (SEMG1; SEMG2) [13; 14] , and fibronectin [13] , as well as laminin and gelatin [15] . PSA in seminal fluid occurs predominantly in an active single-chain form. A minor fraction is inactivated due to internal cleavages [9; 12] or complex formation with the protein C inhibitor (SERPINA5), released from the seminal vesicles [16] [17] [18] . Furthermore, it has been demonstrated that fPSA displays a considerable structural heterogeneity in serum, seminal plasma, and hyperplastic or cancerous tissue [19] . It has been also recently reported that men with male factor infertility have an increased risk of subsequently developing aggressive high-grade prostate cancer [20] . For this reason, it has been suggested that male infertility may be an early and identifiable risk factor for the development of clinically significant prostate cancer.
Posttranslational modifications of the PSA molecule also contribute to the structural heterogeneity. PSA is a glycoprotein composed of approx. 8% N-linked carbohydrate [21] , a biantennary N-linked oligosaccharide of the Nacetyllactosamine type with terminal sialic acid groups [22] . PSA in seminal fluid displays large heterogeneity mainly because of a variable degree of sialylation [23] . It has been shown that the carbohydrate side chains differ greatly in plasma and seminal fluid in PCa patients [24] . Contributing to the heterogeneity of the PSA molecule there are also differences in primary structure, carbohydrate composition and enzymatic activity [7; 23; 25-30] .
Exactly which molecular form(s) of PSA the different commercially available clinical routine assays measure has not been fully elucidated. Differences in the composition of the PSA molecular forms could reflect diversity in the biology of prostate disease, which might be of diagnostic value.
We have previously presented a strategy, that the combination of analytical principles can improve the resolving power of PSA identification, complementarily utilizing 1-D gel electrophoresis and high resolution MALDI-MS, which could confirm complex patterns of PSA forms in seminal plasma [31] .
In the present study we have applied these technology platforms, in addition with clinical data, to characterize the expressed molecular forms of PSA in seminal plasma. Thirty-four participants were enrolled in this study with both healthy controls and patients, i.e., men being diagnosed for infertility. Our study objective was to employ modern proteomic tools to characterize different expression of PSA variants in seminal fluid. Taking into consideration the recent reports on the disease link between male infertility and prostate cancer [20] , the study outcome opens up for functional interpretations related to PSA isoform expression patterns and clinical demography.
Material and Methods

Seminal plasma
Semen samples were obtained from young men undergoing investigation for infertility prior to final diagnosis of disorders and healthy volunteers. Seminal plasma was provided by the Center for Reproductive Medicine at Malmö University Hospital, following the guidelines of the Helsinki Declaration. The collection of seminal plasma was approved by the ethical board at Lund University (approval number: LU 532-03) and the samples were processed according to the WHO guidelines (WHO, 1999). Seminal plasma was prepared by centrifugation at 10,000 g for 10 min and stored at -20°C until use. Table 1 gives details on the clinical data from the participating subjects in the study. Free PSA (fPSA) ranged between 0.233 and 1.915 mg/mL (see Table 1 ) as determined by the DELFIA assay (Perkin Elmer, Turku, Finland) [32] . The total protein content of seminal plasma samples was determined using Bradford reagent (Sigma, Steinheim, Germany) and equal amounts of protein (88 µg) were applied on gels.
The semen volumes are aligned with age matching and the PSA levels measured by ELISA (DELFIA). In addition, we analyzed the fructose levels, because patients with obstruction or aplasia of vas deferens have typically low fructose concentrations. Clinical implication of impaired prostate function is often associated with low zinc levels, whereas the inflammatory status represented by various inflammatory processes (e.g., prostatitis) results in an increased albumin level. Correspondingly, PSA, fructose, zinc and albumin assays were completed and these data are presented in Table 1 . The molecular weights of proteins were calculated by comparing their migration distances to the positions of molecular weight standards, using Quantity One software (Bio-Rad, Hercules, CA). Further on, the major form of PSA (ca. 32 kDa), identified in all samples, was used for normalization of molecular weights of proteins in the gels.
Gel electrophoresis techniques
Mass spectrometry
The major protein bands observed within the size region between 20-40 kDa in SDS-PAGE gels were cut and analyzed by MALDI mass spectrometry following ingel tryptic digestion. All analyses were performed in triplicates. Full mass scans and MS/MS spectra were generated on a MALDI LTQ Orbitrap XL instrument (Thermo Scientific, Bremen, Germany) using two acquisition methods consecutively on each spot. First, the FT mass analyzer (Orbitrap) of the mass spectrometer was utilized for full MS data collection in positive mode within a mass range of 600-4000 Da at 60,000 resolution. Laser energy was set to 10 µJ. 
Data analysis
Protein identification based on high resolution MALDI-MS data was performed The Proteios Software Environment (ProSE) [34] was employed for combining multiple search results using MALDI-MS/MS sequencing data, which is provided by the built-in interfaces of ProSE to protein identification engines [35] . We have simultaneously used both Mascot and X!Tandem with native k-score scoring, searching the IPI Human database [36] version 3.71 (containing 86,745 protein sequences). The precursor mass tolerance was set to 10 ppm, whereas the fragment tolerance was 0.5 Da. The cysteine and methionine residues were modified with fixed carbamidomethylation and variable oxidation, respectively.
The filtering criterion of protein identification was defined as at least two PSA peptides required with an FDR less than 0.01 [35] .
The enzymatically active PSA forms were identified by the tandem mass spectra generated on FT-ICR, using Proteome Discoverer version 1.1 (Thermo Fisher Scientific) applying Mascot search engine on the SwissProt database (March 2010). The database interrogation parameters were set to include the same mass tolerance windows and amino acid modifications as above but two missed cleavages were allowed.
Results and Discussion
We have analyzed seminal plasma samples from young men seeking medical aid due to infertility (n=29) and compared those to healthy controls (n=5). Seminal plasma was chosen in this study because of the fact that the major portion of PSA molecules is in free forms, which enhances the identification of possible PSA isoforms in this proximal fluid. Electrophoretic decomplexing and mass spectrometry based protein identification was employed according to our method reported previously [31] . As Figure 1 Both the free PSA (fPSA) and total protein concentrations of seminal samples were determined by commercial DELFIA and Bradford methods, respectively.
The fPSA values were in the range of 0.233-1.915 mg/mL, whereas the total protein concentration varied between 7.715 and 22.097 mg/mL (see Table 1 ).
The 34 individual samples revealed weak correlation between the level of total protein and PSA expression (correlation coefficient=0.62). With the study nnumber, we were not able to show statistically significant differences in-between total protein-and fPSA-expressions within the two study groups, as shown in Figure 2A . The mean fPSA expression (relative to the total protein levels) was found to be 5% (Figure 2B) , whereas the median value was 4.4%
(minimum=2.0% and maximum=10.4%). Interestingly, four samples clearly deviated from average in the region of high fPSA expression (above 8%),
including one healthy control sample. The other four control samples scattered around the median value. diffusion. Therefore, their optical detection was more difficult, which contributed to a less reliable determination of their molecular weights.
Evaluation of PSA forms in clinical samples
PSA expression in seminal fluid
In gel bands under reducing conditions, we could unambiguously identify single Table. In the remaining of the samples (47%), more than 2 PSA forms could be identified by MS, where 3-9 molecular variants were observed (Figure 3) .
Although, in 2 of these cases Western analysis also indicated multiple PSA forms, the mAb 2E9 missed the clear-cut detection of a significant portion of PSA in the remaining 12 seminal plasma samples.
Since the sample volume applied on gels was normalized to the total protein amount (88 µg), the amount of fPSA varied in the range of 1.78-9.13 µg. We have observed that the higher the fPSA amount in gel the more molecular forms could be identified by MS. In 16 samples more than 2 forms were detected and the relative fPSA expression was above the median value (4.37%) in 12 out of 16, corresponding to 75% of these samples. In those samples, where more than 3 molecular forms of PSA were identified by MS (10 samples in total), 7 samples were within the highest 10 relative fPSA expression levels. On the other hand, in 12 out of 18 cases, where single or double forms of PSA were detected, the relative fPSA expression was below the median value. Interestingly, single PSA forms were detected in two samples (SP13 and SP15) with high relative PSA expression levels. Consequentially, as the strong correlation between the number of observed molecular forms and the amount of PSA applied in gels indicated, more variants could be present in all samples, but the concentration being below the limit of detection.
Enzymatically active PSA forms
The In an attempt to associate the observed enzymatic activity in the zymogram gels with PSA specificity, the unstained bands were subjected to PSA sequencing using the FT-ICR high accuracy mass spectrometer. The FT-ICR platform allowed us to identify PSA forms in the presence of high chemical background. As exemplified with two of the patient samples; SP21 and SP22, we were able to observe 6 enzymatically active bands. Out of these forms, the highest Mw position was detected as 35 kDa, and positively identified as the major form of PSA by FT-ICR with patient SP22 only. The weak activity band in patients SP21 did not allow a positive sequence identity of PSA. Interestingly, patient SP21 showed positive identity by both sequencing, and activity for additionally four PSA forms (29.5, 28.1, 25.4 and 23.9 kDa), whereas the 28.1 kDa PSA form was found to be expressed by patient SP22 as well. The strategy outlined above, allowed us to predict the combined effects of enzyme activity in patient samples with a target identity of PSA.
Correlation analysis
Due to the high resolving power of modern proteomic platforms, we were able to detect the highest number of PSA forms and sequence information that has been identified, as of today, describing a multitude of molecular forms of PSA in seminal fluid. We captured the clinical data of the participants in the study, where age, semen volume, and zinc, fructose and albumin levels were determined. These study data formed the basis for the statistical analysis. The study members were shown to group well in the isomap plot, which lays out the samples in space, revealing the network clustering (see Figure 5A ). Figure 5B shows these separated sample groups as a heat map, where samples with high albumin levels (calculated to be above the third quartile of the data set) gathered in the Red group and to a less extent in the Green group. In addition, the majority of the samples with low fructose and zinc concentrations (which came clear below the first quartile of the data set) were found in the Orange group and to a less extend in the Red group (see Figure 5B ). Interestingly, we found that the samples with low semen volumes in the Red group also have (found below the first quartile of the data set), yet only one patient in this group is identified above the third quartile of age. All of these hierarchical clustering analyses were performed using the Qlucore Omics Explorer v2.1. software.
In the second step of the statistical evaluation, we investigated the Red and Orange groups that proved to have the highest risk for male factor infertility and followed their positioning when the proteomic data were combined with clinical information. Accordingly, besides the clinical data, the levels of fPSA and total protein concentrations, the number of peptides, and the sequences by both MS and Western analysis were included as variables for a multi group comparison.
The following variables remained in this hierarchical clustering analysis after filtering by variance ( / max =0.27): total protein and fructose concentrations, semen volume, age and three identifications of PSA. The resulting isomap and heat map representations revealed a formation of four groups that are displayed in Figure 5C and D. Remarkably, the patients with high albumin levels (Red group in Figure 5A and B) grouped well together in the Yellow group (see Figure   5C and D). These findings are in good correlation with the first analysis round, where the separation of these patients was found to sustain with a strong correlation to an ongoing inflammation. The group of patients with low fructose and zinc levels (Orange group in Figure 5A and B) was also clearly separated in the Green group (Figure 5C and D) .
Interestingly, the samples in the Blue group typically had low semen volumes but without any correlations to additional risk factors. The control samples were grouped in the Red and Blue groups, with a clear separation from the patients with male factor infertility (in the Green and Yellow groups within Figure 5C ).
The peptide sequences as variables from both PMF and MS/MS identification with the major expressed PSA form (at 31.6 kDa) indicated that the number of identified tryptic peptides was one of the most important separating factors in this analysis. Further, detailed investigation of the identified PSA peptide sequences in these separated groups (Yellow and Green in Figure 5C and D) revealed the highest number of peptide annotations.
Conclusions
In our opinion it becomes increasingly evident that PSA as a single marker needs additional and higher resolution data for improved disease speciation and predictive outcome. Despite notable advances in our understanding of the molecular and functional details of PSA, there is still lacking consensus as to which may be the best strategy to obtain optimal clinical value from PSA-testing [19] . 
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